Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors

P.G. Claringbold; R.A. Price; J Turner

doi:10.1089/cbr.2012.1276

Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors

P.G. Claringbold, R.A. Price, J Turner

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	561-569
Journal	Cancer Biotherapy and Radiopharmaceuticals
Volume	27
DOIs	https://doi.org/10.1089/cbr.2012.1276
Publication status	Published - 2012

Access to Document

10.1089/cbr.2012.1276

Cite this

@article{e62e45d14532429fb4450db96df9056f,

title = "Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors",

author = "P.G. Claringbold and R.A. Price and J Turner",

year = "2012",

doi = "10.1089/cbr.2012.1276",

language = "English",

volume = "27",

pages = "561--569",

journal = "Cancer Biotherapy and Radiopharmaceuticals",

issn = "1084-9785",

publisher = "Mary Ann Liebert Inc",

}

TY - JOUR

T1 - Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors

AU - Claringbold, P.G.

AU - Price, R.A.

AU - Turner, J

PY - 2012

Y1 - 2012

U2 - 10.1089/cbr.2012.1276

DO - 10.1089/cbr.2012.1276

M3 - Article

C2 - 23078020

SN - 1084-9785

VL - 27

SP - 561

EP - 569

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

ER -